You wouldn’t think twice about asking your asthma patients to quit smoking, but have you ever asked them whether they have allergic rhinitis? Not such a strange question if you consider that 80% of patients with #asthma have #allergicrhinitis and...
Read moreOPRI is excited to share a milestone in asthma phenotype recognition!
OPRI is excited to share a milestone in asthma phenotype recognition! The ISAR #publication titled, ”Eosinophilic and Non eosinophilic Asthma, An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma...
Read moreAre severe asthma patients getting the right treatment?
Are severe asthma patients getting the right treatment? Research has shown that you can’t take a one-size-fits-all approach to severe asthma management due to differences in phenotypes. So, we developed the International Severe Asthma Registry...
Read moreDDL 2021 Virtual Conference
In this video, DDL Invites Professor David Price to speak in the DDL 2021 Virtual Video Conference, Professor Price explains the changes in GINA asthma management and what does this mean for treating patients with asthma. Check the full...
Read moreWe are delighted to share a new #podcast, “Improving the status quo – can severe asthma be better treated?” on @The Spectator Briefings!
We chat about the experiences of Gabby Perry, a student with severe #asthma, and the dual-edged swords that are steroids. Along with Gabby, Syed Ali, medical affairs manager at AstraZeneca, and OPRI’s own Professor David Price take us through the...
Read moreCONQUEST quality standards: for the COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care
The CONQUEST Quality Standards (QS) aim to enhance care for COPD patients at a higher, yet modifiable, risk of COPD exacerbations, increased morbidity and mortality. Learn more about the QS underpinning the CONQUEST program by viewing this slide...
Read moreEvaluating the impact of targeted, risk-based management in patients with modifiable high-risk COPD
The Observational and Pragmatic Research Institute is proud to announce the launch of the Pragmatic Evaluation of an Improvement Program for People Living with Modifiable High-risk COPD (PREVAIL) study, in collaboration with AstraZeneca and...
Read moreCOVID-19 Quality Improvement Programme for Primary Care
New COVID-19 quality improvement programme available to GP practices across the United Kingdom First-of-its-kind quality improvement programme to exclusively focus on Covid-19 and the management of chronic conditions in the context of a pandemic...
Read moreUsing systemic steroids to manage asthma
Bleecker ER, Menzies-Gow A, Price D, Bourdin A, Sweet S, Martin A, Alacqua M, Tran TN. Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. Am J Respir Crit Care Med. 2020;201:276–93. Steroids, either in the form of...
Read moreImproving patient care for children with asthma: PeARL’s first steps
Mathioudakis AG, Custovic A, Deschildre A, Price D et al. Research priorities in pediatric asthma: Results of a global survey of multiple stakeholder groups by the Pediatric Asthma in Real Life (PeARL) Think Tank. J Allergy Clin Immunol: In Pract...
Read moreAiding physicians in prescribing the right inhaler
World-leading Singapore research institute, the Observational Pragmatic Research Institute (OPRI), is the largest contributor to the global understanding of inhalers for lung disease and was recently featured in a systematic review about the...
Read moreManagement of Asthma in Different Phenotypes – Presented at APSR 2019
Professor David Price recently spoke about the management of asthma in different phenotypes at the Asian Pacific Society of Respirology’s Asthma Symposium 2019. While asthma hospitalization and mortality rates have been declining in past years, a...
Read more